Acorda Therapeutics Gets OK On $185M Ch. 11 Sale To Merz

By Alex Wittenberg · June 7, 2024, 4:49 PM EDT

Drugmaker Acorda Therapeutics Inc. received a New York bankruptcy judge's approval Friday to complete a $185 million sale of its assets to a fellow pharmaceutical company, allowing Acorda to move ahead...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

Acorda Therapeutics, Inc.

Case Number

Court

New York Southern

Nature of Suit

Date Filed

April 01, 2024

Recent Articles By Alex

October 29, 2024
PE-Owned Implant Maker Plagued By Lawsuits Hits Ch. 11
October 15, 2024
Sacklers Say Opioid Claims Can't Undo Purdue Transfers
March 01, 2024
Plaintiffs Blast Prison Health Co.'s 'Potemkin Village' Case
December 20, 2023
Stimwave Buyer Can Enforce Sale In 'Disturbing' Domain Row
December 19, 2023
Zymergen Gets Conditional OK For Ch. 11 Asset Sales
December 01, 2023
Leases Don't Disqualify Small Biz Bankruptcies, Court Rules
November 29, 2023
Oncology Co. Akumin Gets OK For Take-Private Ch. 11 Plan
November 06, 2023
Justices Grant Purdue Creditors Separate Argument Time
October 24, 2023
Med-Tech Co. UpHealth And 6 Units Get OK For Joint Ch. 11
October 23, 2023
High Court Told Purdue's Ch. 11 Liability Waiver Is Legal